Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-279 dose-ranging induction study in moderately to severely active Crohn's disease
2023-506704-14-00Phase 2Authorised
- Sponsor
- Takeda
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing Zasocitinib dose-ranging arm(s) with Placebo arm (2 arms). Primary endpoint: Endoscopic response at Week 12. Planned start Sep 2024; status: authorised.
02
Drugs
zasocitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2023-506704-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506704-14-00.